Healthcare services company Astrana Health will be announcing earnings results tomorrow after market close. Here’s what you need to know.
Astrana Health beat analysts’ revenue expectations by 6.9% last quarter, reporting revenues of $665.2 million, up 88.4% year on year. It was a decent quarter for the company, with full-year revenue guidance beating analysts’ expectations.
Is Astrana Health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Astrana Health’s revenue to grow 57.3% year on year to $636.2 million, improving from the 19.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.33 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Astrana Health has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Astrana Health’s peers in the healthcare technology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Premier’s revenues decreased 8.9% year on year, beating analysts’ expectations by 7.4%, and Omnicell reported revenues up 9.6%, topping estimates by 3.7%.
Read our full analysis of Premier’s results here and Omnicell’s results here.
There has been positive sentiment among investors in the healthcare technology segment, with share prices up 5.9% on average over the last month. Astrana Health is up 3.1% during the same time and is heading into earnings with an average analyst price target of $50.50 (compared to the current share price of $32.04).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
